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Background: Ivacaftor (KALYDECO™, VX-770) is a CFTR potentiator that increased CFTR channel activity and improved lung function in
patients age 6 years and older with CF who have the G551D-CFTR gating mutation. The aim of this in vitro study was to evaluate the effect of
ivacaftor on mutant CFTR protein forms with defects in protein processing and/or channel function.
Methods: The effect of ivacaftor on CFTR function was tested in electrophysiological studies using a panel of Fischer rat thyroid (FRT) cells
expressing 54 missense CFTR mutations that cause defects in the amount or function of CFTR at the cell surface.
Results: Ivacaftor potentiated multiple mutant CFTR protein forms that produce functional CFTR at the cell surface. These included mutant CFTR
forms with mild defects in CFTR processing or mild defects in CFTR channel conductance.
Conclusions: These in vitro data indicated that ivacaftor is a broad acting CFTR potentiator and could be used to help stratify patients with CF who
have different CFTR genotypes for studies investigating the potential clinical beneﬁt of ivacaftor.
© 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: CFTR; Ivacaftor; Potentiator; VX-7701. Introduction
The underlying cause of cystic fibrosis (CF) is the loss of
epithelial chloride transport due to mutations in the CF
transmembrane conductance regulator (CFTR) gene that
encodes the CFTR protein [1]. The CFTR protein is a chloride
channel that is normally present at the cell surface of epithelial
cells, where it is opened and closed (channel gating) by ATP
binding and hydrolysis when activated by protein kinase A
[2–4]. CFTR normally transports chloride to regulate salt, fluid,
and pH balance in multiple organs [5–7]. In people with CF,
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http://dx.doi.org/10.1016/j.jcf.2013.06.008flishedresults in the accumulation of thick, sticky mucus in the bronchi
of the lungs, loss of exocrine pancreatic function, impaired
intestinal absorption, reproductive dysfunction and elevated
sweat chloride concentration [5,8].
More than 1900 CFTR mutations have been identified
(www.genet.sickkids.on.ca). Many of these mutations result in
the loss in chloride transport and presentation of the disease
phenotype, with individual mutations varying widely in their
severity [8] (www.CFTR2.org). Evaluation of the molecular
defect in the CFTR protein caused by CFTR mutations has
shown that the loss of chloride transport can be due to a
reduction in the quantity and/or function of CFTR channels at
the cell surface [9,10]. For example, F508del, which accounts
for approximately two-thirds of all CFTR alleles in people with
CF [8], results in a small amount of F508del-CFTR at the cell
surface due to defects in its protein folding and subsequent
degradation by the endoplasmic reticulum (ER) (class II
mutation)[10]. A decrease in the quantity of CFTR at the cellby Elsevier B.V. All rights reserved.
30 F. Van Goor et al. / Journal of Cystic Fibrosis 13 (2014) 29–36surface can also be due to CFTRmutations that either prevent the
synthesis of full-length CFTR (e.g.,W1282X: class I mutation) or
reduce the amount of CFTR synthesis (e.g., 2789+5G→A: class
V mutation). Other CFTR mutations do not affect the quantity of
CFTR at the cell surface, but cause defects in CFTR channel
gating (e.g., G551D: class III mutation), or reduce the ability of
chloride to pass through the open channel pore (defective channel
conductance; e.g., R334W; class IV mutation) [9–12].
A potential therapeutic strategy to treat CF is to restore the
loss of chloride transport using drugs known as CFTR
modulators [13]. Ivacaftor (also known as KALYDECO™,
VX-770), is a type of CFTR modulator, termed a CFTR
potentiator. CFTR potentiators facilitate increased chloride
transport by potentiating the channel-open probability (or
gating) of the CFTR protein [11]. Ivacaftor has been shown to
potentiate mutant CFTR forms with defects in channel gating
caused by CFTR gating (class III) mutations. These include the
most common CFTR gating mutation, G551D, as well as the
G178R, S549N, S549R, G551S, G970R, G1244E, S1251N,
S1255P, and G1349D mutations [12]. In patients ages 6 years
and older with CF who have the G551D-CFTR gating
mutation, ivacaftor increased chloride transport through CFTR
and improved clinical measures of pulmonary function and
nutritional status [14]. In addition to CFTR gating mutations,
ivacaftor potentiates normal CFTR and F508del-CFTR in in
vitro studies, suggesting that that action of ivacaftor is not
specific for CFTR gating mutations [15].
The aim of this in vitro study was to evaluate the effect of
ivacaftor on mutant CFTR protein forms with defects other than
channel gating. To do this, Ussing chamber electrophysiology
was used to measure chloride transport in a panel of Fischer rat
thyroid (FRT) cell lines engineered to express one of 54 mutant
CFTR forms associated with CF or variable disease consequence,
such as CFTR-related disorders [8,16]. The CFTR mutations
tested result in an amino acid substitution (missense mutations)
and are expected to result in full-length CFTR that exhibit either aN
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Fig. 1. CFTR mRNA expression in FRT cells. Mean (±SEM; n = 3–5) levels of C
containing the Flp Recombination Target site (pFRT/lacZeo). For each mutant CFT
expression for normal CFTR prepared from four separate FRT cell lines. Asteris
(P N 0.05: ANOVA followed by Tukey's multiple comparison test).decrease in the quantity of CFTR on the cell surface
(e.g. defective processing) and/or a decrease in the function of
CFTR (e.g., defective gating and/or conductance).2. Results
2.1. Generation and characterization of a panel of FRT cell
lines expressing mutant forms of CFTR
To allow systematic comparison of the effects of ivacaftor on
54 mutant forms of CFTR, a panel of stable cell lines was
generated using FRT cells. Each cell line in the panel was
engineered to express a single mutant CFTR protein form. The
level of CFTR mRNA expression was generally similar between
normal CFTR and most mutant CFTR protein forms tested
(Fig. 1), suggesting that protein levels among the different mutant
CFTR forms were similar. However, a significantly higher level
(P b 0.05; ANOVA followed by Tukey's multiple comparisons
test; n = 3–6) of mRNA expression was measured for P67L-,
E92K-, and A455E-CFTR (Fig. 1).
To further characterize the cell lines, the delivery of mutant
CFTR protein to the cell surface was indirectly assessed in
immunoblot studies that measure the amount of mature CFTR
(glycosylated) [10]. As expected, due to the presence of varied
mutation types, including processing mutations, there was a wide
range in the ratio of mature to total CFTR (−0.05 to 1.00) and the
level of % normal CFTR (−1.0 to 312.0% of normal) among the
different mutant CFTR forms tested (Table 1; Fig. 2A). For
example, severe processing mutations such as F508del-, R1066H-,
and H1085R-CFTR exhibited a low level of mature CFTR (b5%
normal). Mutations such as P67L-, E56K-, and A455E-CFTR
exhibited intermediate levels of mature CFTR, which are
consistent with less severe defects in CFTR processing (mature
CFTR protein for P67L-, E56K-, and A455E-CFTR were 28.4±
6.8, 12.2±1.5, and 11.5±2.5% of normal, respectively).A5
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FTR mRNA expression for each mutant CFTR form expressed in FRT cells
R form, the level of CFTR mRNA expression was normalized to the level of
ks indicate significant differences compared to normal CFTR mRNA levels
31F. Van Goor et al. / Journal of Cystic Fibrosis 13 (2014) 29–362.2. Baseline chloride transport and response to ivacaftor for
multiple mutant CFTR forms
Consistent with mutations that result in a range of CFTR
quantity and/or function, there was a wide range (0–86.7%able 1
FTR maturation in FRT cells.
utant CFTR form CFTR processing
Mature/total % Normal CFTR
ormal 0.89 ± 0.01 100.0 ± 18.5
85E −0.05 ± 0.04 −1.0 ± 0.9
560S 0.00 ± 0.00 0.0 ± 0.0
1066C 0.02 ± 0.01 0.0 ± 0.0
492F 0.00 ± 0.00 0.1 ± 0.1
560T 0.01 ± 0.01 0.2 ± 0.1
520F 0.05 ± 0.03 0.3 ± 0.2
1101K 0.05 ± 0.03 0.3 ± 0.1
561E 0.08 ± 0.04 0.5 ± 0.2
1066M 0.02 ± 0.02 0.5 ± 0.4
1303K 0.02 ± 0.02 0.5 ± 0.3
559T 0.16 ± 0.09 0.6 ± 0.2
1V 0.06 ± 0.06 0.7 ± 0.6
569D 0.11 ± 0.04 0.6 ± 0.2
1066H 0.08 ± 0.02 a 0.7 ± 0.2 a
1065P 0.05 ± 0.05 1.0 ± 0.8
467P 0.10 ± 0.07 1.2 ± 0.8
1077P 0.08 ± 0.04 1.5 ± 0.6
46D 0.21 ± 0.08 1.9 ± 0.5 a
92K 0.06 ± 0.05 1.9 ± 1.3
1054D 0.09 ± 0.04 1.9 ± 0.8
508del 0.09 ± 0.02 a 2.3 ± 0.5 a
1085R 0.06 ± 0.01 a 3.0 ± 0.7 a
336K 0.42 ± 0.05 a 6.5 ± 0.7 a
206W 0.35 ± 0.10 a 6.8 ± 1.7 a
1074L 0.52 ± 0.03 a 10.9 ± 0.6 a
455E 0.26 ± 0.10 a 11.5 ± 2.5 a
56K 0.29 ± 0.04 a 12.2 ± 1.5 a
347P 0.48 ± 0.04 a 14.6 ± 1.8 a
1070W 0.61 ± 0.04 a 16.3 ± 0.6 a
67L 0.36 ± 0.04 a 28.4 ± 6.8 a
1070Q 0.90 ± 0.01 a 29.5 ± 1.4 a
977F 0.97 ± 0.01 a 37.3 ± 2.4 a
1067T 0.78 ± 0.03 a 38.6 ± 6.1 a
579G 0.72 ± 0.02 a 39.3 ± 3.1 a
1270N 1.00 ± 0.00 a,c 40.7 ± 1.2 a
945L 0.65 ± 0.04 a 42.4 ± 8.9 a
927P 0.89 ± 0.01 a,b 43.5 ± 2.5 a,b
117C 0.87 ± 0.02 a,b 49.1 ± 2.9 a,b
338I 0.93 ± 0.03 a,b 54.2 ± 3.7 a,b
997F 0.90 ± 0.04 a,b 59.8 ± 10.4 a,b
110H 0.97 ± 0.01 a,b 60.6 ± 1.5 a,b
341P 0.79 ± 0.02 a 65.0 ± 4.9 a,b
668C 0.94 ± 0.03 a,b 68.5 ± 1.9 a,b
74W 0.78 ± 0.01 a 69.0 ± 2.7 a,b
110E 0.92 ± 0.05 a,b 87.5 ± 9.5 a,b
334W 0.91 ± 0.05 a,b 97.6 ± 10.0 a,b
1060T 0.87 ± 0.02 a,b 109.9 ± 28.0 a,b
347H 0.96 ± 0.02 a,c 120.7 ± 2.8 a,b
1235R 0.96 ± 0.00 a,c 139.0 ± 9.0 a,b
193K 0.84 ± 0.02 a,b 143.0 ± 17.1 a,b
117H 0.86 ± 0.01 a,b 164.5 ± 34.2 a,b
352Q 0.98 ± 0.01 a,b 179.9 ± 8.0 a,c
1052V 0.90 ± 0.01 a,b 189.9 ± 33.1 a,b
1152H 0.96 ± 0.02 a,c 312.0 ± 45.5 a,b
Notes to Table 1:
Quantification of steady-state CFTR maturation expressed as the mean (±SEM;
n = 5–9) ratio of mature CFTR to total CFTR (immature plus mature) or level
of mature mutant CFTR relative to mature normal-CFTR (% normal CFTR) in
FRT cells individually expressing CFTR mutations.
a Mean level for the ratio of mature to total CFTR or % normal CFTR was N3
standard deviations from zero.
b Normal CFTR processing (% normal mature CFTR P N 0.05 vs. normal CFTR).
c Abnormally high CFTR processing (% normal mature P b 0.05 vs. normal)
(unpaired t-test; n = 3–16).T
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Dnormal CFTR) in baseline chloride transport among the different
mutant CFTR forms as determined by Ussing chamber studies
(Table 2; Fig. 2B). Because CFTR requires activation by PKA,
baseline chloride transport was determined in the presence of
10 μM forskolin. The range in baseline chloride transport did not
appear to be due to differences in CFTR mRNA levels or total
protein levels (mature + immature) for most mutant CFTR
forms. However, the following four exceptions were noted. The
estimated total protein level for R117C-CFTR (38 ± 5% normal
CFTR) was lower (P b 0.05; ANOVA followed by Tukey's least
significant difference test; n = 12) compared with normal CFTR,
suggesting that the baseline level of chloride transport may be
underestimated. In contrast, the estimated total protein levels for
E193K-CFTR (177 ± 12% normal CFTR; n = 6), R352Q-CFTR
(178 ± 4% normal CFTR; n = 6), and D1152H-CFTR (256 ±
16% normal CFTR; n = 9) were higher (P b 0.05; ANOVA
followed by Tukey's least significant difference test) compared
with normal CFTR, suggesting that the baseline chloride
transport may be overestimated by ~1.8 to 2.6 fold for these
three mutant CFTR forms.
Acute (5-min) addition of ivacaftor following CFTR
activation by forskolin significantly (P = 0.05; paired t-test)
increased chloride transport over baseline for a number of the
mutant CFTR forms tested (Table 2; Fig. 2B). The net increase
over baseline chloride transport by ivacaftor (ivacaftor response
minus baseline) ranged from 1.8 to 155.0% of normal CFTR,
reaching maximum sustained levels of 2.1 to 200.7% of normal
CFTR (Table 2; Fig. 2B). The fold increase over baseline
chloride transport (ivacaftor response divided by baseline)
ranged from 1.6 to 52.0 (Table 2). The EC50 of ivacaftor for all
mutant CFTR forms tested was similar to G551D-CFTR
(range; 101 to 735 nM) (Table 2; Fig. 3). The remaining
mutant CFTR forms had no significant response to ivacaftor
under the experimental conditions used in this study (Table 2;
Fig. 2B).
3. Discussion
Both in vitro and natural history studies have demonstrated
that CFTR mutations are associated with variation in the
severity of the loss of chloride transport and disease phenotype,
the most severe form of which is CF [8,16]. The objective of
this study was to systematically evaluate the effect of ivacaftor
on multiple mutant CFTR forms in vitro using a panel of 54
FRT cell lines, each expressing a single mutant form of CFTR
produced by a missense mutation. We focused on missense
mutations that would be expected to produce a range of CFTR
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Fig. 2. CFTR maturation, baseline chloride transport, and ivacaftor response in FRT cells expressing CFTR mutations. A) CFTR maturation as a percentage of normal
mature CFTR in FRT cells expressing the CFTR mutant forms indicated (filled bars). Asterisks indicate mean level of mature CFTR normalized to % normal CFTR
was N3 standard deviations from zero. B) Baseline chloride transport (filled bars) and ivacaftor (10 μM) response (open bars) in FRT cells expressing the CFTR
mutant forms indicated. Asterisks indicate significant increase over baseline chloride transport (P b 0.05, paired t-test; n = 3–6) in response to ivacaftor addition.
Chloride transport was measured in Ussing chamber studies and expressed as a percentage of the mean transepithelial current in four FRT cell lines expressing normal
CFTR (% normal). All data in A and B were ranked according to the baseline chloride transport.
32 F. Van Goor et al. / Journal of Cystic Fibrosis 13 (2014) 29–36function and which corresponded to a range of disease severity,
including CF and CFTR-related disorders. Excluded from the
analysis were nonsense and canonical splice mutations that
would be expected to produce no full length CFTR, as well as
splice mutations associated with the production of normal
levels of CFTR mRNA. Also excluded were CFTR gating
mutations as these data have been previously reported [12].
The mutant CFTR forms studied here exhibited a wide range
in the level of baseline chloride transport, from 0 to 86.7% of
normal CFTR. This was expected, as the CFTR mutations
tested include known or putative CF-causing mutations, as wellas CFTR mutations associated with varying clinical conse-
quences (e.g., R668C, F1052V, D1152H) or complex CFTR
alleles that may modify disease severity (e.g., S1235R)
(www.CFTR2.org) [8,16]. Ivacaftor potentiated 34 of the 54
mutant CFTR forms expressed as determined by Ussing
chamber electrophysiology, suggesting that it is a broad-
acting CFTR potentiator. However, the magnitude of the
responses to ivacaftor varied widely. Because the level of
CFTR mRNA was similar across the panel of cell lines
tested, the range in baseline activity and ivacaftor response
likely reflects the severity of the functional defect and/or the
Table 2
Baseline chloride transport and maximum ivacaftor response in a panel of FRT cell lines expressing multiple mutant CFTR forms.
Mutation Patients a Chloride transport (μA/cm2) Chloride transport (% normal) EC50
Baseline With ivacaftor Baseline With ivacaftor Fold increase over baseline b
Normal 204.5 ± 33.3 301.3 ± 33.8 c 100.0 ± 16.3 147.3 ± 16.5 c 1.5 266 ± 42
G551D 1282 1.5 ± 0.7 113.2 ± 13.0 c 1.0 ± 0.5 55.3 ± 6.3 c 55.3 312 ± 73
F1052V 12 177.3 ± 13.7 410.2 ± 11.3 c 86.7 ± 6.7 200.7 ± 5.6 c 2.3 177 ± 14
S1235R ND 160.6 ± 25.7 352.1 ± 43.4 c 78.5 ± 12.6 172.2 ± 21.2 c 2.2 282 ± 104
D1152H 185 117.3 ± 23.0 282.7 ± 46.9 c 57.4 ± 11.2 138.2 ± 22.9 c 2.4 178 ± 67
D1270N 32 109.5 ± 20.5 209.5 ± 27.4 c 53.6 ± 10.0 102.4 ± 13.4 c 1.9 254 ± 56
R668C 45 99.0 ± 9.4 217.6 ± 11.7 c 48.4 ± 4.6 106.4 ± 5.7 c 2.2 517 ± 105
K1060T ND 89.0 ± 9.8 236.4 ± 20.3 c 43.5 ± 4.8 115.6 ± 9.9 c 2.7 131 ± 73
R74W 25 86.8 ± 26.9 199.1 ± 16.8 c 42.5 ± 13.2 97.3 ± 8.2 c 2.3 162 ± 17
R117H 739 67.2 ± 13.3 274.1 ± 32.2 c 32.9 ± 6.5 134.0 ± 15.7 c 4.1 151 ± 14
E193K ND 62.2 ± 9.8 379.1 ± 1.1 c 30.4 ± 4.8 185.4 ± 1.0 c 6.1 240 ± 20
A1067T ND 55.9 ± 3.2 164.0 ± 9.7 c 27.3 ± 1.6 80.2 ± 4.7 c 2.9 317 ± 214
L997F 27 43.7 ± 3.2 145.5 ± 4.0 c 21.4 ± 1.6 71.2 ± 2.0 c 3.3 162 ± 12
R1070Q 15 42.0 ± 0.8 67.3 ± 2.9 c 20.6 ± 0.4 32.9 ± 1.4 c 1.6 164 ± 20
D110E ND 23.3 ± 4.7 96.4 ± 15.6 c 11.4 ± 2.3 47.1 ± 7.6 c 4.1 213 ± 51
D579G 21 21.5 ± 4.1 192.0 ± 18.5 c 10.5 ± 2.0 93.9 ± 9.0 c 8.9 239 ± 48
D110H 30 18.5 ± 2.2 116.7 ± 11.3 c 9.1 ± 1.1 57.1 ± 5.5 c 6.2 249 ± 59
R1070W 13 16.6 ± 2.6 102.1 ± 3.1 c 8.1 ± 1.3 49.9 ± 1.5 c 6.2 158 ± 48
P67L 53 16.0 ± 6.7 88.7 ± 15.7 c 7.8 ± 3.3 43.4 ± 7.7 c 5.6 195 ± 40
E56K ND 15.8 ± 3.1 63.6 ± 4.4 c 7.7 ± 1.5 31.1 ± 2.2 c 4.0 123 ± 33
F1074L ND 14.0 ± 3.4 43.5 ± 5.4 c 6.9 ± 1.6 21.3 ± 2.6 c 3.1 141 ± 19
A455E 120 12.9 ± 2.6 36.4 ± 2.5 c 6.3 ± 1.2 17.8 ± 1.2 c 2.8 170 ± 44
S945L 63 12.3 ± 3.9 154.9 ± 47.6 c 6.0 ± 1.9 75.8 ± 23.3 c 12.6 181 ± 36
S977F 9 11.3 ± 6.2 42.5 ± 19.1 c 5.5 ± 3.0 20.8 ± 9.3 c 3.8 283 ± 36
R347H 65 10.9 ± 3.3 106.3 ± 7.6 c 5.3 ± 1.6 52.0 ± 3.7 c 9.8 280 ± 35
L206W 81 10.3 ± 1.7 36.4 ± 2.8 c 5.0 ± 0.8 17.8 ± 1.4 c 3.6 101 ± 13
R117C 61 5.8 ± 1.5 33.7 ± 7.8 c 2.9 ± 0.7 16.5 ± 3.8 c 5.7 380 ± 136
R352Q 46 5.5 ± 1.0 84.5 ± 7.8 c 2.7 ± 0.5 41.3 ± 3.8 c 15.2 287 ± 75
R1066H 29 3.0 ± 0.3 8.0 ± 0.8 c 1.5 ± 0.1 3.9 ± 0.4 c 2.6 390 ± 179
T338I 54 2.9 ± 0.8 16.1 ± 2.4 c 1.4 ± 0.4 7.9 ± 1.2 c 5.6 334 ± 38
R334W 150 2.6 ± 0.5 10.0 ± 1.4 c 1.3 ± 0.2 4.9 ± 0.7 c 3.8 259 ± 103
G85E 262 1.6 ± 1.0 1.5 ± 1.2 0.8 ± 0.5 0.7 ± 0.6 NS NS
A46D ND 2.0 ± 0.6 1.1 ± 1.1 1.0 ± 0.3 0.5 ± 0.6 NS NS
I336K 29 1.8 ± 0.2 7.4 ± 0.1 c 0.9 ± 0.1 3.6 ± 0.1 c 4 735 ± 204
H1054D ND 1.7 ± 0.3 8.7 ± 0.3 c 0.8 ± 0.1 4.2 ± 0.1 c 5.3 187 ± 20
F508del 29,018 0.8 ± 0.6 12.1 ± 1.7 c 0.4 ± 0.3 5.9 ± 0.8 c 14.8 129 ± 38
M1V 9 0.7 ± 1.4 6.5 ± 1.9 c 0.4 ± 0.7 3.2 ± 0.9 c 8.0 183 ± 85
E92K 14 0.6 ± 0.2 4.3 ± 0.8 c 0.3 ± 0.1 2.1 ± 0.4 c 7.0 198 ± 46
V520F 58 0.4 ± 0.2 0.5 ± 0.2 0.2 ± 0.1 0.2 ± 0.1 NS NS
H1085R ND 0.3 ± 0.2 2.1 ± 0.4 0.2 ± 0.1 1.0 ± 0.2 NS NS
R560T 180 0.3 ± 0.3 0.5 ± 0.5 0.1 ± 0.1 0.2 ± 0.2 NS NS
L927P 15 0.2 ± 0.1 10.7 ± 1.7 c 0.1 ± 0.1 5.2 ± 0.8 c 52.0 313 ± 66
R560S ND 0.0 ± 0.1 −0.2 ± 0.2 0.0 ± 0.0 −0.1 ± 0.1 NS NS
N1303K 1161 0.0 ± 0.0 1.7 ± 0.3 0.0 ± 0.0 0.8 ± 0.2 NS NS
M1101K 79 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 NS NS
L1077P 42 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 NS NS
R1066M ND 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 NS NS
R1066C 100 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 NS NS
L1065P 25 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 NS NS
Y569D 9 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 NS NS
A561E ND 0.0 ± 0.1 0.0 ± 0.1 0.0 ± 0.0 0.0 ± 0.1 NS NS
A559T 43 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 NS NS
S492F 16 0.0 ± 0.0 1.7 ± 1.2 0.0 ± 0.0 0.8 ± 0.6 NS NS
L467P 16 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 NS NS
R347P 214 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 NS NS
S341P 9 0.0 ± 0.0 0.2 ± 0.2 0.0 ± 0.0 0.1 ± 0.1 NS NS
a Number of individuals with the individual mutation in the CFTR-2 database (www.CFTR2.org).
b The fold increase over baseline was determined by dividing the level of chloride transport (% normal) in the presence of ivacaftor by the baseline chloride
transport.
c Significant difference compared to baseline (P b 0.05; paired t-test; n = 3–7; NS indicates P N 0.05).
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Fig. 3. Concentration response curve for ivacaftor in FRT cells expressing CFTR mutations that responded to ivacaftor. A–H) Concentration response curve at the
indicated ivacaftor concentrations from Ussing chamber studies using FRT cells expressing a single mutant CFTR form (n = 4–20). I) Expanded y-axis for selected
data shown in panels G and H.
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different CFTR mutations. For example, the baseline level of
chloride transport and ivacaftor response was higher for
mutant CFTR forms associated with mild defects in CFTR
processing (e.g., E56K, P67L, L206W, A455E, D579G,
S945L, S977F, A1067T, R1070Q, R1070W, F1074L, and
D1270N) than for those associated with severe defects in
CFTR processing (e.g., F508del, H1054D, R1066H). Sim-
ilarly, the baseline chloride transport and ivacaftor response
were higher for mutant CFTR forms with mild defects in
channel conductance (30–84% of normal; D110H-, R347H,
and R352Q-CFTR) [17–19], compared with those with
severe defects in CFTR channel conductance (undetectable
R334W- and T338I-CFTR) [9,20]. This is consistent with
previous studies that showed ivacaftor increases the channel
open probability (channel gating activity), but does not alterthe single channel current amplitude (a measure of channel
conductance) [11,12]. For mutant CFTR forms that have
multiple defects (e.g., R117H, F508del, S945L, R1070Q,
A1067T, R1070W, and R347P), the relative impact of each
defect is likely to affect the magnitude of the baseline chloride
transport and ivacaftor response in vitro and in a clinical setting.
For example, the channel open probability and conductance of
R117H-CFTR were reported to be 28% and 86% of normal
CFTR, respectively [9]. This suggests that the R117H mutation
may be associated with defective channel gating, as well as
conductance defects, and may explain why the ivacaftor response
was larger than for CFTR mutations that result in defects in
conductance alone (e.g., R347H, R352Q).
Mutant CFTR forms that did not significantly respond to
ivacaftor under the experimental conditions used in this study
were generally associated with severe defects in CFTR processing
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CFTR at the cell surface. The lack of response was expected, as
ivacaftor acts on CFTR at the cell surface to enhance chloride
transport. However, some exceptions were noted. The most
common CF mutation, F508del-CFTR, showed a small, but
measurable level of mature F508del-CFTR in FRT cells (Table 2;
Fig. 2), which was potentiated by ivacaftor. These results are
consistent with a small, but measurable response to ivacaftor in
primary cultures of human bronchial epithelial cells isolated from
some patients with CF who are homozygous for F508del [11]. A
small but significant response to ivacaftor was also observed in
FRT cells expressing the severe processing mutations, M1V,
H1054D, and I336K (Table 2; Fig. 2).
Our understanding of the molecular and functional defects in
CFTR caused by the many different types of CFTR mutations
has been greatly facilitated by grouping them into five classes
based on the associated molecular defect [8,10]. Indeed, the
category of gating mutations (class III) has proven useful to
predict mutant CFTR forms that are highly responsive to
ivacaftor [12]. However, the data presented here suggest that
these classifications may not be generally predictive of a
pharmacological response to a potentiator. For example, among
the processing mutations (class II) tested, the baseline chloride
transport and the net increase over baseline in response to
ivacaftor ranged from 0 to 54% of normal CFTR and 0 to 70%
of normal CFTR, respectively. Similarly, among conductance
mutations (class IV) the baseline chloride transport and the net
increase over baseline in response to ivacaftor ranged from 0 to
~33% of normal CFTR and 0 to ~101% of normal CFTR,
respectively. A similar range in baseline chloride transport, as
determined by sweat chloride measurements, has been ob-
served within a single mutation class in patients with CF. For
example, patients with CF who have the class II mutation, P67L,
along with a severe CF-causing mutation (most commonly
F508del), have a mean sweat chloride concentration of
57 mmol/L [21], which is lower than that in patients with CF
who carry two copies of the most common class II mutation,
F508del (~100 mmol/L). Similarly, patients with CF who have
the most common class IV mutation, R117H, typically have a
lower sweat chloride concentration than those with R347P
(60 mmol/L vs. 99 mmol/L, respectively) [22]. Also, a single
CFTRmutation can result in multiple molecular defects in CFTR,
the combined effect of which will likely determine the overall
severity of the functional defect. As a result, the combined use of a
class definition along with the functional characteristics (level of
baseline chloride transport) was better correlated with the response
to ivacaftor for each CFTR mutation.
These in vitro data examined the baseline levels of chloride
transport and the response to ivacaftor for single CFTR
mutations. Although not the scope of this study, variations in
the baseline level of CFTR chloride transport and the response to
ivacaftor among people carrying the same CFTR mutation may
occur due to a variety of factors, including differences in the
CFTRmutation on the second allele or the presence of a complex
CFTR allele that modulates CFTR protein levels. A complex
CFTR allele occurs when two functional DNA alterations occur
on the same parentalCFTR gene (in cis). For example, the R117HCFTR mutation is relatively common among people heterozy-
gous for the F508del CFTR mutation and is frequently identified
in newborn screening programs [8,16]. When the R117H CFTR
mutation is found on the same CFTR gene (in cis) with the 5T
mutation (5 thymidine repeats in intron 8) a milder form of CF
characterized by pancreatic sufficiency may be present, whereas
when the 7T mutation in cis with R117H is found, CFTR-related
disorders or no disease may be present. This difference in clinical
consequence is likely due to the lower amount of CFTR protein
synthesized in people with the 5T mutation compared to those
with the 7T mutation. Other examples of complex CFTR alleles
include the number of TG repeats in intron 8 along with the 5T
CFTR mutation (e.g., TG11-5T, TG12-5T, TG13-5T), R668C-
G576A-D443Y, and R74W-D1270N [8,16]. The extent to which
complex CFTR alleles impact the clinical response to ivacaftor
remains to be determined. Additional factors not associated with
the CFTR genemay also impact the clinical response to ivacaftor
and include modifier genes, environmental factors, disease
severity at the time of treatment, and pharmacokinetics.
This study focused on the effect of ivacaftor alone. The
level of the response to ivacaftor, however, can be affected by
inducing or augmenting the level of CFTR activity by using
additional pharmacological agents. For instance, insufficient
amounts of mutant CFTR at the cell surface can be augmented
or increased by using an additional pharmacological agent,
which promotes an increase in the level of functional CFTR at
the cell surface, thereby enhancing the overall impact of
ivacaftor. CFTR correctors, for example, which increase the
amount of functional CFTR at the cell surface, have been
shown to augment the effect of ivacaftor in vitro. Further
studies are needed to characterize the effects of drug
combinations on the panel of mutations presented in this
study.
Given the range in the response to ivacaftor among the
different mutant CFTR forms tested in vitro, an important open
question is how this range may translate into clinical benefit in
CF. The shared characteristics of the mutant CFTR forms that
responded to ivacaftor in vitro included normal or mild defects in
CFTR processing, indicating that CFTR is present at the cell
surface, and electrophysiological evidence of residual baseline
chloride transport. In people with CF, these mutant CFTR forms
are typically associated with common clinical measures of
residual CFTR function, such as lower incidence of pancreatic
insufficiency, sweat chloride levels typically below 90 mmol/L,
or a measurable increase in chloride transport in nasal potential
difference studies [8,23]. It may be possible to use clinical
measures of residual CFTR function in addition to, or along with
genotype, to select people with CF for clinical studies evaluating
the benefit of ivacaftor monotherapy.
In conclusion, ivacaftor potentiated multiple mutant CFTR
forms produced by missense CFTR mutations expressed in a
panel of FRT cells. These in vitro studies along with in vivo
measures of residual CFTR function, such as exocrine
pancreatic function or sweat chloride concentrations, could be
used to help stratify patients with CF who have different CFTR
genotypes for studies investigating the potential clinical benefit
of ivacaftor.
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4.1. Cell line generation
A panel of FRT cell lines expressing different CFTR
mutations was generated using a host cell line with a single
integration site as described in the supplementary material.
4.2. RNA analysis
Total RNA was isolated and real-time PCR assays were
performed as described in the supplementary material.
4.2.1. Electrophysiology
Ussing chamber techniques using FRT cells were used to
record the IT due to CFTR-mediated chloride transport (see
supplementary material). Baseline chloride transport in a panel of
FRT cell lines expressing mutant CFTR forms was assessed by
Ussing chamber electrophysiology. To monitor baseline chloride
transport, CFTR was activated by addition of 10 μM forskolin to
increase the intracellular levels of cAMP and activate protein
kinase A. Chloride transport was expressed as a percentage of the
baseline chloride transport measured in four separate FRT cell
lines expressing normal CFTR (% normal-CFTR; 204.5 ±
29.8 μA/cm2).
4.3. CFTR
4.3.1. Immunoblot analysis
Immunoblot techniques using the monoclonal CFTR antibody
769 (J. Riordan, University of North Carolina) were used to
measure CFTR maturation in FRT cells expressing wild-type- or
F508del-CFTR (see supplementary material). The ratio of
steady-statemature to steady-state total CFTR (mature + immature
CFTR) was used to estimate the fraction of CFTR synthesized that
was processed and delivered to the cell surface. In addition, the
steady-state level of mature mutant CFTR was expressed as a
percentage of normal mature CFTR (% normal CFTR) as
measured in four separate FRT cell lines expressing normal
CFTR. The amount ofmaturemutant CFTR in immunoblot studies
has been shown to linearly correlate with other measures of cell
surface CFTR [24], suggesting that it is a good indicator of the
steady-state amount of CFTR at the cell surface.
Appendix A. Supplementary data
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.jcf.2013.06.008.
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